The Manufacturers Life Insurance Company Cuts Stock Position in Tarsus Pharmaceuticals, Inc. $TARS

Posted by Stanley Muller on Aug 9th, 2026

The Manufacturers Life Insurance Company trimmed its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 32.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,404 shares of the company’s stock after selling 17,879 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.09% of Tarsus Pharmaceuticals worth $2,624,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Quantinno Capital Management LP boosted its holdings in shares of Tarsus Pharmaceuticals by 22.7% in the first quarter. Quantinno Capital Management LP now owns 3,367 shares of the company’s stock valued at $236,000 after acquiring an additional 622 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Tarsus Pharmaceuticals by 14.5% in the 1st quarter. Renaissance Technologies LLC now owns 73,400 shares of the company’s stock valued at $5,149,000 after purchasing an additional 9,300 shares in the last quarter. Gabelli Funds LLC acquired a new position in Tarsus Pharmaceuticals during the 1st quarter worth approximately $253,000. Pale Fire Capital SE increased its position in Tarsus Pharmaceuticals by 130.5% during the 1st quarter. Pale Fire Capital SE now owns 5,652 shares of the company’s stock worth $396,000 after purchasing an additional 3,200 shares during the period. Finally, Lido Advisors LLC purchased a new position in shares of Tarsus Pharmaceuticals during the 1st quarter worth approximately $1,710,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals News Roundup

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

Positive Sentiment: XDEMVY sales continued to accelerate. Second-quarter net product sales reached $173.9 million, up more than 69% year over year and ahead of analysts’ expectations of approximately $169.7 million. The company projected 2026 XDEMVY net sales of $685 million to $705 million, supporting the investment case for its approved Demodex blepharitis treatment. Tarsus second-quarter results
Positive Sentiment: Tarsus is expanding into a potentially significant retinal-disease market. The company agreed to acquire Alkeus Pharmaceuticals and its Phase 3-stage oral candidate gildeuretinol (ALK-001), which targets Stargardt disease. The transaction gives Tarsus a potential blockbuster opportunity in a disease with no FDA-approved therapy and broadens its pipeline beyond XDEMVY. Alkeus acquisition
Neutral Sentiment: Analyst expectations remain above the current trading level. Recent price targets cited by Quiver Quantitative range from $88 to $105, with a $90 median target, although these targets may not yet fully reflect the Alkeus transaction or updated execution risks.
Negative Sentiment: The quarterly loss was materially worse than expected. Tarsus reported a loss of $0.43 per share versus consensus estimates for a loss of roughly $0.19 to $0.21, despite revenue exceeding forecasts. The company remains unprofitable, which can increase sensitivity to spending and deal-related costs. Tarsus Q2 earnings report
Negative Sentiment: The Alkeus deal and financing create near-term execution and dilution concerns. The acquisition has a potential value of up to $800 million, including $450 million in upfront consideration, while Tarsus separately announced a $125 million private placement. Investors may be concerned about capital needs, share dilution and the clinical and regulatory risks of ALK-001. Tarsus Alkeus acquisition announcement Tarsus private placement

Insider Transactions at Tarsus Pharmaceuticals

In other news, insider Jeffrey S. Farrow sold 14,396 shares of the business’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $60.95, for a total transaction of $877,436.20. Following the completion of the sale, the insider owned 56,801 shares in the company, valued at approximately $3,462,020.95. The trade was a 20.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Bobak R. Azamian sold 10,000 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $61.55, for a total transaction of $615,500.00. Following the sale, the chief executive officer directly owned 847,991 shares of the company’s stock, valued at approximately $52,193,846.05. This trade represents a 1.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 39,850 shares of company stock worth $2,452,821 over the last 90 days. Company insiders own 9.64% of the company’s stock.

Tarsus Pharmaceuticals Price Performance

Shares of Tarsus Pharmaceuticals stock opened at $64.79 on Friday. Tarsus Pharmaceuticals, Inc. has a twelve month low of $47.21 and a twelve month high of $85.25. The stock has a market capitalization of $2.79 billion, a P/E ratio of -59.44 and a beta of 0.53. The company has a current ratio of 3.74, a quick ratio of 3.71 and a debt-to-equity ratio of 0.21. The business’s fifty day moving average price is $61.39 and its 200 day moving average price is $64.94.

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.24). The firm had revenue of $173.91 million for the quarter, compared to analyst estimates of $169.65 million. Tarsus Pharmaceuticals had a negative return on equity of 13.57% and a negative net margin of 7.67%. As a group, research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -1.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on TARS shares. Mizuho cut their price target on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating for the company in a report on Friday, July 31st. HC Wainwright reissued a “buy” rating and issued a $88.00 price target on shares of Tarsus Pharmaceuticals in a report on Thursday, July 9th. Wall Street Zen cut Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Oppenheimer started coverage on shares of Tarsus Pharmaceuticals in a research note on Friday, April 24th. They issued an “outperform” rating and a $98.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $90.17.

Get Our Latest Research Report on Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Company Profile

(Free Report)

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.